Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

Study identifier:RDEA3170-206

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 2a, Randomized, Open-Label Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Allopurinol Compared With Allopurinol Administered Alone in Adult Subjects With Gout

Medical condition

Gout

Phase

Phase 2

Healthy volunteers

No

Study drug

RDEA3170 2.5 mg, allopurinol 300 mg

Sex

All

Actual Enrollment

40

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 01 Jul 2015
Estimated Primary Completion Date: 01 Dec 2015
Estimated Study Completion Date: 01 Jan 2016

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2015 by Ardea Biosciences, Inc.

Sponsors

Ardea Biosciences, Inc.

Collaborators

-

Inclusion and exclusion criteria